The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020

Changes over time for: Section 2B

Version Superseded: 27/01/2022

Alternative versions:

Status:

Point in time view as at 18/01/2022. This version of this provision has been superseded.

Status

You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.

Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.

Changes to legislation:

There are currently no known outstanding effects for the The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020, Section 2B.

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

[F1Requirements on person notified as a close contact of a person who has tested positive for coronavirusE+W

This adran has no associated Memorandwm Esboniadol

2B.—(1) This regulation applies where an adult is notified by a relevant person, other than by means of the NHS Covid 19 smartphone app developed and operated by the Secretary of State, that—

(a)they have had close contact with someone who has tested positive for coronavirus, F2...

F3(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F4(ba). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F5(c). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(2) Where paragraph (1)(a) applies, the person notified must self-isolate for the period of self-isolation unless [F6paragraph (6) applies or]—

(a)they are taking part in coronavirus related research, and

(b)that research cannot be completed if they self-isolate.

F7(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F8(3A) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F9(3B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(4) In addition, P F10... F11... must if, requested by a relevant person, notify that person of the address at which P will remain pursuant to the requirement in regulation 2(1)(a).

(5) If a relevant person notifies P F12... F13... that a notification referred to in paragraph (1) in respect of P is withdrawn, such notification is deemed never to have been given for the purposes of these Regulations.

F14(5A) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F15(5B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[F16(6) This paragraph applies if—

[F17(a)the person (“NP”)—

(i)has completed a course of doses of—

(aa)an authorised vaccine, or

(bb)a vaccine under the United Kingdom vaccine roll-out overseas,

and the relevant day is more than 14 days after the day on which NP completed that course of doses, and

(ii)is able to provide proof that the requirement in paragraph (i) is satisfied to a relevant person or an authorised person upon request,]

[F18(b)NP—

(i)has participated, or is participating, in a relevant clinical trial of a vaccine for vaccination against coronavirus, and

(ii)is able to provide proof of such participation to a relevant person or an authorised person upon request,] or

[F19(c)NP—

(i)has been advised by a registered medical practitioner that for clinical reasons NP should not be vaccinated with an authorised vaccine, and

(ii)is able to provide proof of such advice through a relevant document if required to do so by a relevant person or an authorised person.]

(7) For the purposes of paragraph (6), a person has completed a course of doses if that person has received the complete course of doses [F20—

(a)specified—

(i)in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or

(ii)in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 for the authorised vaccine, or

(b)of a vaccine under the United Kingdom vaccine roll-out overseas as specified in the manufacturer’s guidance for that vaccine.]

[F21(7A) For the purposes of paragraph (6)(a)—

(a)“the relevant day” means—

(i)where the person who has tested positive for coronavirus with whom NP has had close contact (“C”) is a member of the same household as NP—

(aa)the date which C reported to a relevant person as the date on which symptoms first developed, or

(bb)if C has no symptoms of coronavirus, the day on which C took the test for coronavirus which resulted in a positive result, or

(ii)in any other case, the day on which NP had the close contact which resulted in the notification described in paragraph (1);

(b)proof that the requirement in paragraph (6)(a)(i)(aa) has been satisfied must be provided by—

(i)the NHS COVID pass, or equivalent from NHS Scotland, NHS Wales or the Department of Health in Northern Ireland,

(ii)the EU Digital COVID Certificate,

(iii)a North American Certificate,

(iv)a COVID-19 vaccination certificate issued by an approved third country or territory and considered by the European Commission to be equivalent to an EU Digital COVID Certificate issued in accordance with Regulation (EU) 2021/953,

(v)the Centers for Disease Control and Prevention vaccination card, or

(vi)a vaccine certificate,

and for these purposes, “NHS COVID pass”, “NHS Scotland”, “NHS Wales”, the “EU Digital COVID Certificate”, “North American Certificate” and “vaccine certificate” have the same meanings as in Part 1B of the International Travel Regulations.]

[F22(7AA) For the purposes of paragraph (6)(b)—

(a)“a relevant clinical trial” means—

(i)a clinical trial carried out in the United Kingdom in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004,

(ii)a clinical trial regulated in the United States of America by the Food and Drugs Administration, or

(iii)phase 2 (therapeutic exploratory studies) or phase 3 (clinical efficacy and safety studies) of a clinical trial regulated by an approved regulator;

(b)proof of participation in a relevant clinical trial referred to in sub-paragraph (a)(ii) or (iii) must be provided through—

(i)a vaccination card issued by the Centers for Disease Control and Prevention, in the case of a clinical trial referred to in sub-paragraph (a)(ii), or

(ii)a participation document, in the case of a clinical trial referred to in sub-paragraph (a)(iii).

(7AB) In paragraph (7AA)—

(a)“approved regulator” means—

(i)the European Medicines Agency, or

(ii)a regulatory authority (other than such an authority in the United Kingdom or the United States of America) which is designated as a Stringent Regulatory Authority by the World Health Organization;

(b)“participation document” means a document in English, French or Spanish issued by the competent health authority of the country or territory in which the relevant clinical trial is being, or was, carried out, or the person who is conducting, or conducted, the relevant clinical trial, which confirms—

(i)NP’s full name;

(ii)NP’s date of birth;

(iii)the name and manufacturer of the vaccine;

(iv)the country or territory in which the clinical trial is taking, or took, place;

(v)the regulatory authority responsible for the regulation of the clinical trial;

(vi)the phase of the clinical trial in which NP is participating or participated.]

[F23(7B) For the purposes of this regulation—

(a)NP is deemed to have completed a course of doses of an authorised vaccine if—

(i)NP has received at least 2 doses of any of the vaccines referred in sub-paragraph (c)(ii) of the definition of “authorised vaccine” in regulation 3A(2) of the International Travel Regulations, or

(ii)NP has received a dose of one authorised vaccine and a dose of a different authorised vaccine;

(b)NP is deemed to have completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas if—

(i)NP has received a dose of an authorised vaccine and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, or

(ii)NP has received a dose of one vaccine under the United Kingdom vaccine roll-out overseas, and a dose of a different vaccine under the United Kingdom vaccine roll-out overseas.]

(8) In this regulation—

[F24“authorised person” has the meaning given in regulation 12(12);]

[F25“authorised vaccine” has the same meaning as in Part 1B of the International Travel Regulations;]

“clinical trial” has the meaning given in regulation 2(1) (interpretation) of the Medicines for Human Use (Clinical Trials) Regulations 2004;

[F26“the International Travel Regulations” means the Health Protection (Coronavirus, International Travel and Operator Liability) (England) Regulations 2021;]

“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012;

[F27“marketing authorisation” has the same meaning as in Part 1B of the International Travel Regulations;]

“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012.]

[F28“relevant document” means—

(a)

a letter issued by the NHS in response to an NHS COVID pass medical exemptions application,

(b)

a certification in paper or electronic form issued by NHS Scotland, or

(c)

a maternity certificate which satisfies the requirements of—

(i)

regulation 2(3) of the Social Security (Medical Evidence) Regulations 1976, or

(ii)